CONCENTRA GROUP HOLDINGS PARENT IN (CON)

Sector: Health Care

    Home/Companies/CON/Annual Meeting

2026 Annual Meeting Analysis

CONCENTRA GROUP HOLDINGS PARENT IN · Meeting: April 30, 2026

Policy v1.2high confidenceView Filing ↗
For informational purposes only. This AI-generated analysis applies a published voting policy to publicly available proxy filings. It does not constitute investment advice, proxy voting advice, or a solicitation of any kind. AI analysis may be incomplete or inaccurate — always review the actual filing and make your own independent decision.

Directors FOR

3

Directors AGAINST

0

Say on Pay

FOR

Auditor

FOR

Director Elections

Election of Class II Directors

3 FOR
✓ FOR
William K. Newton

Newton has served as a director since June 2024 (approximately 1.5 years of tenure), which is within the 24-month new-director exemption window; additionally, CON's 3-year price return of -0.8% outperforms the IHF benchmark return of -10.2% by +9.4 percentage points, well below the 20pp trigger threshold for negative absolute TSR, so no TSR concern applies.

✓ FOR
Marc R. Watkins, M.D.

Watkins has served since July 2024 (approximately 1.5 years), placing him within the 24-month new-director exemption; the company's TSR also outperforms IHF by +9.4pp, meaning no performance-based trigger fires in any case.

✓ FOR
Vipin Gopal

Gopal joined in July 2025 and has served less than 12 months, making him fully exempt from the TSR trigger under the 24-month new-director exemption policy; he brings relevant data analytics and healthcare industry expertise.

All three Class II nominees are well within the 24-month new-director exemption period, the company's stock has outperformed its IHF benchmark by +9.4 percentage points over three years, all directors attended 100% of meetings, no overboarding issues are present, and the board discloses a skills matrix — no policy triggers fire for any nominee.

Say on Pay

✓ FOR

CEO

William K. Newton

Total Comp

$7,399,513

Prior Support

78.4%%

The prior year Say on Pay vote received 78.4% support, comfortably above the 70% threshold that would require a response assessment. CEO total compensation of $7,399,513 is composed of approximately 11% base salary ($843,077), 59% stock awards ($4,356,000), and 29% performance bonus ($2,125,000), meaning roughly 89% of the CEO's pay is variable — well above the 50-60% variable pay minimum required by policy. The company's annual bonus plan is tied to specific EBITDA and earnings-per-share targets with defined threshold, target, and maximum levels, and a clawback policy compliant with NYSE listing standards is in place, so no meaningful red flags exist in the compensation structure.

Auditor Ratification

✓ FOR

Auditor

PricewaterhouseCoopers LLP

Tenure

N/A

Audit Fees

$2,186,000

Non-Audit Fees

$2,000

Non-audit fees of $2,000 represent less than 0.1% of audit fees of $2,186,000, far below the 50% threshold that would raise independence concerns; PwC is a Big 4 firm appropriate for a $2.8B market cap company; tenure is not disclosed but the tenure trigger requires confirmed data to fire, so no negative inference is drawn.

Overall Assessment

Concentra's 2026 annual meeting presents a clean ballot with three straightforward FOR votes: all Class II director nominees are new to the board and exempt from TSR scrutiny, PwC's non-audit fees are negligible relative to audit fees, and the executive compensation program is heavily variable with above-threshold prior shareholder support. No stockholder proposals appear on this year's ballot.

Filing date: March 17, 2026·Policy v1.2·high confidence

Compensation Peer Group

1 companies disclosed in 2026 proxy filing

IHF__INDEX_BENCHMARK__:S&P Health Care Services Select Industry Index (proxy: IHF — iShares U.S. Healthcare Providers ETF)